Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment
Open Access
- 31 January 2014
- journal article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (1) , R36
Abstract
Introduction: The patient’s perspective is becoming increasingly important in clinical and policy decisions. In this study, we aimed to evaluate the preferences of patients with, or at risk of, osteoporosis for medication attributes, and to establish how patients trade between these attributes. Methods: A discrete choice experiment survey was designed and patients were asked to choose between two hypothetical unlabelled drug treatments (and an opt-out option) that vary in five attributes: efficacy in reducing the risk of fracture, type of potential common side-effects, mode and frequency of administration and out-of-pocket costs. An efficient experimental design was used to construct the treatment option choice sets and a mixed logit panel data model was used to estimate patients’ preferences and trade-offs between attributes. Results: A total of 257 patients with, or at risk of, osteoporosis completed the experiment. As expected, patients preferred treatment with higher effectiveness and lower cost. They also preferred either an oral monthly tablet or 6-month subcutaneous injection above weekly oral tablets, 3-month subcutaneous, 3-month intravenous or yearly intravenous injections. Patients disliked being at risk of gastro-intestinal disorders more than being at risk of skin reactions and flu-like symptoms. There was significant variation in preferences across the sample for all attributes except subcutaneous injection. Conclusions: This study revealed that osteoporotic patients preferred 6-month subcutaneous injection and oral monthly tablet, and disliked gastro-intestinal disorders. Moreover, patients were willing to pay a personal contribution or to trade treatment efficacy for better levels of other attributes. Preferences for treatment attributes varied across patients and this highlights the importance of clinical decision-making taking individual preferences into account to improve osteoporosis care.Keywords
This publication has 28 references indexed in Scilit:
- The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in SwedenBMC Musculoskeletal Disorders, 2012
- Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task ForceValue in Health, 2011
- Salzburg statement on shared decision makingBMJ, 2011
- Discrete choice experiments in health economics: a review of the literatureHealth Economics, 2010
- Conjoint Analysis Applications in Health – How are Studies being Designed and Reported?The Patient - Patient-Centered Outcomes Research, 2010
- Patient preferences for osteoporosis in Spain: a discrete choice experimentOsteoporosis International, 2010
- Patients’ preferences for osteoporosis drug treatment: a discrete choice experimentOsteoporosis International, 2008
- Patient treatment preferences for osteoporosisArthritis Care & Research, 2006
- Discrete choice experiments in health careBMJ, 2004
- Improving Health Care by Understanding Patient Preferences: The Role of Computer TechnologyJournal of the American Medical Informatics Association, 1998